scholarly journals AB0055 SOLUBLE TREM-1 LEVELS IN FAMILIAL MEDITERRANEAN FEVER RELATED AA-AMYLOIDOSIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1329.2-1330
Author(s):  
S. Ugurlu ◽  
B. H. Egeli ◽  
I. M. Bolayirli ◽  
H. Ozdogan
Keyword(s):  
Familial Mediterranean Fever ◽  
Demographic Data ◽  
Enzyme Linked Immunosorbent Assay ◽  
Aa Amyloidosis ◽  
Control Groups ◽  
Tertiary Center ◽  
Healthy Control ◽  
Mediterranean Fever ◽  
The Mean

Background:Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) is a monocyte and neutrophil receptor functioning in innate immunity. TREM-1 produces proinflammatory cytokines and serves for neutrophil degranulation. TREM-1 activity is well known in the pathogenesis of sepsis; hence it can be also present in autoinflammatory diseases such as the most common monogenic one, Familial Mediterranean Fever (FMF).Objectives:The objective of this study is to measure soluble TREM-1 (sTREM-1) activity in severe FMF cases complicated with systemic AA-Amyloidosis.Methods:The cohort of the study includes regularly followed FMF related AA-Amyloidosis patients in a tertiary center outpatient rheumatology clinic. Soluble TREM-1 levels were measured using enzyme-linked immunosorbent assay (ELISA). In addition, demographic data, renal function tests, acute phase reactants, and medical prescription history was also noted and analyzed. None of the FMF diagnosed patients had an attack during the collection of the blood samples.Results:The patients were categorized into 4 groups: FMF related AA-Amyloidosis patients (A(+) FMF(+)), FMF unrelated AA-Amyloidosis (FMF(-) A(+)), FMF patients without Amyloidosis diagnosis (FMF(+) A (-)), and healthy controls (HC). The mean ages, TREM-1, C - reactive protein (CRP), and Creatinine levels of each group are shown in Table 1. TREM-1 levels were found to be significantly higher in A(+) FMF(+) group than FMF(+) A (-), and healthy control groups (p= 0.001 and 0.002). Nevertheless, this difference was not found in between A(+) FMF(+) and FMF(-) A(+) (p= 0.447). In addition, the TREM-1 levels of FMF(+) A (-), and healthy control groups were not different (0.532). In A(+) FMF(+) group, 36 patients used colchicine with the mean dose of 1.9±0.8 mg/day, 14 patients used anakinra, and 9 patients used canakinumab. In FMF(+) A (-) group all 20 patients used colchicine with the mean dose of 2.8±0.9 mg/day, 1 patient used anakinra, and 2 patients used canakinumab.Table 1.Clinical Features of Patients and TREM-1 levelsA(+) FMF(+)(n= 42)FMF(-) A(+)(n=5)FMF(+) A(-)(n=20)HC(n=20)Age43.9±12.954.8±1935.3±9.6435.4±6.57TREM-1735.3±566.51247.1±1349.2414.3±142.3439.2±104.6CRP11.1±14.251.3±98.325.8±541.8±1.7Creatinine1.6±1.83.28±4.170.7±0.150.7±0.15Conclusion:In conclusion, TREM-1 is a proinflammatory marker found significantly high in AA-amyloidosis patients regardless of their FMF diagnosis. TREM-1 may be useful in AA-amyloidosis follow-up and early diagnosis since currently there is a deficit of an early diagnostic marker of amyloidosis. This study is a cross-sectional one so it is hard to reach a conclusion on the effectiveness of TREM-1 during regular FMF follow-up for the secondary prevention of amyloidosis. However, the sensitivity of TREM-1 as a marker cannot be denied in amyloidosis.Disclosure of Interests:None declared

scholarly journals Evaluation of E148Q and Concomitant AA Amyloidosis in Patients with Familial Mediterranean Fever

2021 ◽  
Vol 10 (16) ◽  
pp. 3511
Author(s):  
Zehra Serap Arici ◽  
Micol Romano ◽  
David Piskin ◽  
Ferhat Guzel ◽  
Sezgin Sahin ◽  
...  
Keyword(s):  
Familial Mediterranean Fever ◽  
Clinical Phenotype ◽  
Clinical Manifestations ◽  
Histopathological Diagnosis ◽  
Close Monitoring ◽  
Aa Amyloidosis ◽  
Homozygous Genotype ◽  
Age Of Diagnosis ◽  
Mediterranean Fever

The aim of the study was to compare the clinical phenotype of patients with familial Mediterranean fever (FMF)-related AA amyloidosis, according to the age of FMF diagnosis and E148Q genotype. Patients with biopsy-confirmed FMF-related AA amyloidosis were included in the study. Tel-Hashomer criteria were applied in the diagnosis of FMF. All patients had detailed baseline assessment of clinical features, renal functions, genetic testing, histopathological diagnosis of amyloidosis, and treatment received. Multiple comparisons were performed according to the age of diagnosis, disease phenotype, mutation, and mortality. Our study included 169 patients with a diagnosis of AA amyloidosis. There were 101 patients diagnosed with FMF < 18 years of age and 68 patients diagnosed who were ≥18 years of age. The three most common clinical manifestations were fever (84.6%), abdominal pain (71.6%), and arthritis (66.9%). The most common allele among FMF patients was M694V (60.6%), followed by E148Q (21.4%), and M680I (10.3%). The most frequent genotypes were M694V/M694V (45.0%), M694V/E148Q (14.8%), and E148Q/E148Q (11.2%) among 169 patients in our cohort. During the follow-up period, 15 patients (10 male, 5 female) died, of whom 14 had M694V homozygous genotype and one was homozygous for E148Q. Clinicians should be aware of patients with homozygous E148Q genotype for close monitoring and further evaluation. The possible relationship between E148Q and AA amyloidosis needs to be confirmed in other ethnicities.

scholarly journals P1723CLINICAL AND LABORATORY CHARACTERISTICS OF RENAL TRANSPLANT PATIENTS WITH AA AMYLOIDOSIS IN A TERTIARY CENTER IN TURKEY

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Ece Bilgic ◽  
Rezzan Eren Sadioğlu ◽  
Şahin Eyüpoğlu ◽  
Akın fırat Kocaay ◽  
ACAR TUZUNER ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Clinical Laboratory ◽  
Aa Amyloidosis ◽  
Transplant Patients ◽  
Predictive Parameters ◽  
Tertiary Center ◽  
Insufficient Response ◽  
Mediterranean Fever ◽  
The Mean ◽  
Renal Transplant Patients

Abstract Background and Aims Despite improved therapeutic regimens, AA amyloidosis is still associated with higher risk of mortality after renal transplantation (RT). Moreover the clinical, laboratory characteristics and prognostic factors remain poorly understood. We aimed to identify predictive parameters of prognosis, investigate the etiology, clinical and laboratory features of renal transplant patients with biopsy proven AA amyloidosis. Method We conducted a retrospective study using twenty-eight renal transplant patients with AA amyloidosis and twenty-eight renal transplant control patients without amyloidosis matched for age and time after transplantation that were regularly followed in University of Ankara School of Medicine Nephrology Department between October 2018-October 2019. Causes of AA amyloidosis, treatment (colchicine and/ or anti-interleukin (IL) 1 treatment) and number of Familial Mediterranean Fever (FMF) attacks in the last year in case of FMF, biochemical values such as mean CRP, hemoglobin, serum albumin, proteinuria, glomerular filtration rate (GFR), serum creatinine levels were compared between groups. Results In amyloidosis and non-amyloiodosis group, the mean age was 44±13 and 44±12 years; 57% and 54% were males, mean time after transplantation was 95±64 and 93±12 month, respectively. FMF was found as the most common cause of AA amyloidosis (86%). All FMF patients received colchicine and eight (33%) FMF patients with AA amyloidosis with insufficient response to colchicine were treated with anti-IL-1 agents. The mean colchicine dose was 0,92±0,34 mg/day. The mean GFR were 63±24 ml/dk/1,73 m2 in amyloidosis and 71±19 ml/dk/1,73 m2 in non amyloidosis group, (p=0.195). The most important finding of present study was significantly higher CRP levels in patients with AA amyloidosis compared to non-amyloidosis group (15,12±15,16 mg/L vs 6,59±8,20 mg/L, p=0,011, respectively). Conclusion In this study, we found higher CRP levels in renal transplant patients with AA amyloidosis which indicates persistent ongoing chronic inflammation among these patients. Figure Clinical and Laboratory Characteristics of Patient Groups

scholarly journals POS1372 EVALUATION OF E148Q AND CONCOMITANT AA AMYLOIDOSIS SECONDARY TO FAMILIAL MEDITERRANEAN FEVER AFTER ADJUSTED CLINICAL-DEMOGRAPHIC CHARACTERISTICS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 968.1-968
Author(s):  
Z. S. Arici ◽  
M. Romano ◽  
D. Piskin ◽  
F. Guzel ◽  
M. Yilmaz ◽  
...  
Keyword(s):  
Family History ◽  
Familial Mediterranean Fever ◽  
Allele Frequency ◽  
Demographic Characteristics ◽  
Renal Amyloidosis ◽  
Histopathological Diagnosis ◽  
Aa Amyloidosis ◽  
History Of ◽  
Mediterranean Fever

Background:Amyloid A (AA) amyloidosis, previously known as secondary or reactive amyloidosis, is a long-recognized severe complication of some chronic inflammatory diseases. The pathogenesis and risk factors for amyloidosis in Familial Mediterranean Fever (FMF) remain partially understood (1). The development of AA amyloidosis is dependent on ethnicity and country of residence (2). In the pre-colchicine era, renal AA-amyloidosis was largely reported patients of Turkish (67%) and Sephardic Jewish ancestry (26.5%) (2,3). Currently it’s well known that the MEFV M694V variant associated with high risk of amyloidosis however, mutations on exon 2, specifically E148Q variant remained controversial.Objectives:To evaluate the E148Q mutation variant and concomitant AA Amyloidosis secondary to FMF after adjusted clinical-demographic characteristics.Methods:Patients were recruited from the renal unit at Epigenetic Health Center outpatient clinic in Turkey between September 2003 and February 2020. Patients who had biopsy confirmed FMF related AA amyloidosis were included the study. Tel-Hashomer criteria were applied in the diagnosis of FMF. The clinical characteristics of FMF patients and medication history were recorded by the physician at the time of registry entry. All patients had detailed baseline assessment of clinical features, renal functions, genetic testing, histopathological diagnosis of amyloidosis, and treatment received. We performed multiple comparisons according to the age of diagnosis, demographic features, disease phenotype, allele frequency, type of mutation and mortality. Statistical analysis was performed with Statistical Package of Social Science (SPSS) for Windows, version 15.0 (SPSS Inc, Chicago, IL).Results:Our registry consists of 195 patients with a diagnosis of AA amyloidosis. Complete information on 169 patients (lost to follow up, n=26) were included. The median age was 36 (19-49) years; male/female ratio was 1.6 (104/65). The median follow-up duration was 15.0 years (4-17 years). There were 101 patients diagnosed with FMF <18 years of age and 68 patients diagnosed ≥18 years of age. All participants developed renal amyloidosis before the age of 32 years. Family history of FMF was documented in 56 patients (33.1%) and family history of amyloidosis was present in 41 patients (24.3%). The three most common clinical symptoms were fever (84,6%), abdominal pain (71.6%) and arthritis (66.9%). During the follow-up, 5 patients started dialysis treatment and 9 patients had kidney transplantation. The most common allele frequency across patients was M694V (60.6%), E148Q (21.4%) and M680I (10.3%). The most frequent mutations were M694V/M694V (63.3%), M694V/E148Q (20.8%) and E148Q/E148Q (15.8%). During the follow up period, 15 patients (10 male, 5 female) died. In those that died, the mutations in 14 had M694V/M694Vand one demonstrated E148Q/E148Q.Conclusion:Patients with FMF related AA amyloidosis have an increased risk for mortality. This study confirmed the association between M694V and FMF-associated AA amyloidosis, which has been reported in many studies. Close clinical follow-up and further evaluation of patients with the E148Q mutation is warranted specifically if residing in FMF endemic areas. The possible relationship between E148Q and AA amyloidosis need to be confirmed in other cohorts.References:[1]Erer B, Demirkaya E, Ozen S, Kallinich T. What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review. Rheumatology international. 2016;36(4):483-7.[2]Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis and rheumatism. 2007;56(5):1706-12.[3]Pras M, Bronshpigel N, Zemer D, Gafni J. Variable incidence of amyloidosis in familial Mediterranean fever among different ethnic groups. Johns Hopkins Med J. 1982;150(1):22-6.Disclosure of Interests:None declared

Evaluation of Gas6 and sAxl levels during attacks and attack-free periods of familial Mediterranean fever

2018 ◽  
Vol 43 (5) ◽  
pp. 475-480
Author(s):  
Gokhan Cakirca ◽  
Muhammet Murat Celik
Keyword(s):  
Familial Mediterranean Fever ◽  
Specific Protein ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Significant Difference ◽  
Healthy Control ◽  
Mediterranean Fever

Abstract Objectives: We aimed to assess the growth arrest specific protein 6 (Gas6) and soluble Axl (sAxl) levels in the familial Mediterranean fever (FMF) patients, and to investigate the correlation between the levels of these with the inflammatory markers including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and fibrinogen. Materials and methods: Seventy nine FMF patients (35 in attack period and 44 in attack-free period) and 40 healthy controls were involved in the study. The levels of serum Gas6 and sAxl were measured by enzyme-linked immunosorbent assay (ELISA) method. Results: Gas6 levels of the FMF patients with attack were significantly lower than both the attack-free patients and the healthy controls (p=0.007 and p=0.003, respectively). However, no significant difference was detected between the Gas6 levels of the attack-free patients and the healthy controls (p>0.05). sAxl levels of the FMF patients with attack were significantly lower than the healthy control (p=0.007). A positive correlation was found between the Gas6 and CRP levels of the FMF patients with attack (r=0.379, p=0.025). Conclusions: This study indicates that decreased serum Gas6 and sAxl levels may be associated with FMF attack period. Further studies on the role of the Gas6/Axl system in FMF are needed.

scholarly journals In familial Mediterranean fever, soluble TREM-1 plasma level is higher in case of amyloidosis

2019 ◽  
Vol 25 (8) ◽  
pp. 487-490 ◽  
Author(s):  
Clémence Gorlier ◽  
Jérémie Sellam ◽  
Ludivine Laurans ◽  
Tabassome Simon ◽  
Irina Giurgea ◽  
...  
Keyword(s):  
Serum Level ◽  
Familial Mediterranean Fever ◽  
Protein Level ◽  
Demographic Data ◽  
Normal Serum ◽  
Soluble Form ◽  
Blood Levels ◽  
Aa Amyloidosis ◽  
Amyloid A ◽  
Mediterranean Fever

We aimed to explore triggering receptor expressed on myeloid cells-1 (TREM-1) activation in familial Mediterranean fever (FMF), the most frequent monogenic auto-inflammatory disease, through the measurement of its serum soluble form, named sTREM-1. Blood samples from patients with FMF according to Livneh criteria followed in the French FMF national center and carrying two pathogenic MEFV mutations were collected. Serum level of sTREM-1 was assessed using ELISA. Demographic data, presence of FMF attack, association with histologically proven AA amyloidosis, and blood levels of C-reactive protein (CRP), serum amyloid A (SAA) protein, and creatinine were collected. TREM-1 was available in 56 patients (33.9% male, mean age 43 yr); AA amyloidosis was associated in six patients (19.6% in FMF). Mean sTREM-1 level did not differ significantly between patients having an attack or not and there was also no significant correlation between the level of sTREM-1 and CRP and SAA protein. However, the mean rate of sTREM-1 was significantly higher among FMF patients with AA amyloidosis versus without, though the concomitant SAA protein level was normal. Serum level of sTREM-1 was higher in patients with amyloidosis even though the concomitant SAA protein level was normal. sTREM-1 plasma levels could be an accurate tool to specifically identify FMF patients with amyloidosis.

scholarly journals Serum Leptin Is not a Diagnostic Marker for Familial Mediterranean Fever Attacks

2006 ◽  
Vol 2006 ◽  
pp. 1-5
Author(s):  
Bülent Toy ◽  
Orhan Tarçın ◽  
Sait Bağcı ◽  
Yücel Üstündağ ◽  
Ali Inal ◽  
...  
Keyword(s):  
Familial Mediterranean Fever ◽  
Serum Levels ◽  
Control Group ◽  
Serum Leptin ◽  
Reactive Protein ◽  
Mediterranean Fever ◽  
Leukocyte Counts ◽  
The Mean ◽  
Fever Attacks

The aim of our study is to determine whether there is a relationship between familial Mediterranean fever (FMF) attacks and serum leptin levels. We enrolled 25 patients (22 males and 3 females) and 25 healthy controls (21 males and 4 females) with a mean age of24.42±1.22(Mean±SEM) years and24.30±1.19years (Mean±SEM), respectively. We investigated serum levels of leptin, interleukin-6 (IL-6) erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fibrinogen, and leukocyte counts before the attack and 8–12 hours after the attack started. The same parameters have been investigated in the control subjects. The mean serum leptin levels before the attacks were6.45±1.05(Mean±SEM) and during the attacks were7.59±1.3(Mean±SEM) in FMF group, respectively. There was a slight increase in serum leptin levels during the attacks but it was not statistically significant (P>.05). The mean serum leptin levels were6.12±2.81in the control group which were not different from the mean serum leptin levels before and during the attack periods in the study group (P>.05). However, there were statistical differences in the serum levels of IL-6, ESR, CRP, fibrinogen, and leukocyte counts before and during the attack periods (P<.05). No correlation was found between serum leptin levels and IL-6, ESR, CRP, fibrinogen, and leukocyte counts (P>.05). Serum leptin levels do not increase during FMF attacks and therefore it is not useful for diagnostic purposes and follow-up during treatment.

scholarly journals Flow diverter stents in the treatment of recanalized intracranial aneurysms

2021 ◽  
pp. 159101992199050
Author(s):  
Erol Akgul ◽  
Hasan Bilen Onan ◽  
Irem Islek ◽  
Mehmet Tonge ◽  
Yavuz Durmus ◽  
...  
Keyword(s):  
Intracranial Aneurysms ◽  
Demographic Data ◽  
Previous Treatment ◽  
Flow Diverter ◽  
Serious Adverse Events ◽  
Clinical Complications ◽  
Tertiary Hospitals ◽  
The Mean ◽  
Technical Complication

Background We assessed the safety and efficacy of flow diverter stents (FDSs) in the treatment of recanalized or residual intracranial aneurysms treated endovascularly. Materials & Methods Patients whose recanalized or residual aneurysms were treated with FDSs in five tertiary hospitals were reviewed retrospectively. The patients’ demographic data, aneurysm characteristics, types of previous treatment, and clinical complications, or serious adverse events associated with FDSs, as well as the results of neurological and angiographic follow-up assessments, were recorded. Results Eighty-six patients (37 males) with 87 aneurysms were included in this study. Eighty (91.9%) aneurysms were in the anterior and seven (8.1%) in the posterior circulation. The initial treatment methods were the primary coiling or balloon remodeling technique in 69 (79.3%) and stent-assisted coiling in 18 (20.7%) aneurysms. The endovascular procedure was successful in all patients. Complications occurred in four patients, for a total complication rate of 4.6%. A technical complication developed in one patient (1.2%). An in-stent thrombosis treated with tirofiban was seen in two cases. Late in-stent stenosis exceeding 50% was treated with balloon angioplasty in one patient. The mean length of follow-up was 21.0 months. The first angiographic follow-up (3–6 months) revealed the complete occlusion of 74 aneurysms (85.1%). While 76 aneurysms (87.4%) were occluded at the last angiographic follow-up (mean: 26.0 months), 11 aneurysms (12.6%) were still filling. Morbimortality was zero. Conclusion The drawback of endovascular treatment is aneurysmal remnants or recurrences, which is safely and durably amenable to flow diversion.

scholarly journals AB1065 VISIT COMPLIANCE IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM A GAZI UNIVERSITY FMF COHORT

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1822.1-1822
Author(s):  
R. Bilici Salman ◽  
A. Avanoğlu Güler ◽  
H. Satiş ◽  
H. Karadeniz ◽  
H. Babaoglu ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Family History ◽  
Familial Mediterranean Fever ◽  
Predictive Factors ◽  
Severity Score ◽  
Comorbid Disease ◽  
Rheumatology Clinic ◽  
Mediterranean Fever ◽  
One Year

Background:Follow-up in all rheumatologic patients is critical, particularly Familial Mediterranean Fever (FMF). Current recommendations for all experts by the EULAR state that patients with FMF should be evaluated 6-monthly intervals to monitore the character and frequency of the attacks and the acute phase response. Disease-related complications such as amyloidosis can beasymptomaticand need only a careful follow-up.Objectives:to quantify this phenomenon and to find predictive factors of visit compliance in patients with FMF.Methods:The study included 474 adult patients with a diagnosis of FMF who followed at the outpatient rheumatology clinic of tertiary university hospital, from January 2018 to December 2018. . Demographic, socioeconomic data, familiy history, comorbid disease, medication history, characteristics, the International Severity Score for FMF (ISSF),autoinflammatory disease damage index (ADDI) were recorded. Visit compliance was defined as the presence of two visits in the outpatient rheumatology clinic for FMF last one year for the purposes set out in EULAR suggestion.Those who had fewer than two visits in the last one year were considered noncompliant.Results:230 (48.5%) were compliant while 244 (51.5 %) patients were noncompliant with their rheumatology visit. Both compliant and noncompliant patients had similar median age and disease duration. Female sex and being married was increased the visit compliance.The results of the logistic regression model exploring factors associated with compliance indicated that presence of family history in parents, absence of family history in sibling, treatment with biologic agents, other drug using,presence of more than 2 attacks except fever and adequate medical care were important predictors of visit compliance.Conclusion:In conclusion, if FMF patients visit compliance increase, their functionality, medication adherence and quality of life will increase and flares and complication of disease can decrease. Thus, we highlight some recommendations for FMF specialist, patients and health care providers to improve outcomes.Table 2.Multivariate logistic regression analysis for predictive factors of visit compliance of the patients with FMF, n=430Adj. OR%95 CI**pFamily history in parents(positive history vs negative)1,81,0-3,10.03Family history in sibling(negative history vs positive)1,91,2-3,10.004Comorbid disease status1,30,7-2,50.32Treatment(anakinra&canakinumab vs colchicine)3,71,7-8,20.001Drug using(other drugs vs FMF drugs)2,21,1-4,40.01More than 2 attacks except fever2,31,2-4,00.004Chronic peripheral arthritis2,30,8-6,60.10Proteinuria2,20,7-6,70.14Adequate medical care1,91,2-3,10.003Number of index flare within last 12-month0,90,9-1,00.38ISSF severity score0,80,7-1,10,30Disclosure of Interests:None declared

Thyroid disorders in familial Mediterranean fever: think about AA amyloidosis!

2021 ◽  
Author(s):  
Hélène Vergneault ◽  
Rim Bourguiba ◽  
Samuel Ardois ◽  
Anael Dumont ◽  
Léa Savey ◽  
...  
Keyword(s):  
Familial Mediterranean Fever ◽  
Thyroid Disorders ◽  
Aa Amyloidosis ◽  
Mediterranean Fever

scholarly journals Autologous Matrix-Induced Chondrogenesis for Treatment of Focal Cartilage Defects in the Knee: A Follow-up Study

2021 ◽  
Vol 9 (2) ◽  
pp. 232596712098187
Author(s):  
Justus Gille ◽  
Ellen Reiss ◽  
Moritz Freitag ◽  
Jan Schagemann ◽  
Matthias Steinwachs ◽  
...  
Keyword(s):  
Repeated Measures ◽  
Demographic Data ◽  
Case Series ◽  
Defect Size ◽  
Lysholm Score ◽  
Outcome Analysis ◽  
Cartilage Defects ◽  
Chondral Defects ◽  
The Mean

Background: Autologous matrix-induced chondrogenesis (AMIC) is a well-established treatment for full-thickness cartilage defects. Purpose: To evaluate the long-term clinical outcomes of AMIC for the treatment of chondral lesions of the knee. Study Design: Case series; Level of evidence, 4. Methods: A multisite prospective registry recorded demographic data and outcomes for patients who underwent repair of chondral defects. In total, 131 patients were included in the study. Lysholm, Knee injury and Osteoarthritis Outcome Score (KOOS), and visual analog scale (VAS) score for pain were used for outcome analysis. Across all patients, the mean ± SD age of patients was 36.6 ± 11.7 years. The mean body weight was 80.0 ± 16.8 kg, mean height was 176.3 ± 7.9 cm, and mean defect size was 3.3 ± 1.8 cm2. Defects were classified as Outerbridge grade III or IV. A repeated-measures analysis of variance was used to compare outcomes across all time points. Results: The median follow-up time for the patients in this cohort was 4.56 ± 2.92 years. Significant improvement ( P < .001) in all scores was observed at 1 to 2 years after AMIC, and improved values were noted up to 7 years postoperatively. Among all patients, the mean preoperative Lysholm score was 46.9 ± 19.6. At the 1-year follow-up, a significantly higher mean Lysholm score was noted, with maintenance of the favorable outcomes at 7-year follow-up. The KOOS also showed a significant improvement of postoperative values compared with preoperative data. The mean VAS had significantly decreased during the 7-year follow-up. Age, sex, and defect size did not have a significant effect on the outcomes. Conclusion: AMIC is an effective method of treating chondral defects of the knee and leads to reliably favorable results up to 7 years postoperatively.

Sign in / Sign up

Export Citation Format

Share Document